Pamidronatdinatrium

Phase 2Small molecule

UUniversity of Aarhus

Pamidronatdinatrium is one of 51 small molecule programs targeting Osteomyelitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteomyelitisActive, not recruiting

OsteomyelitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Osteomyelitis

#DrugCompanyPhaseTrials

Azulfidine

Pfizer

Approved

1 2

Rifadin

Sanofi

Approved

1 3

Cipro

Zyvox

Priftin

Maxipime

Acanya

Avelox

Mycobutin

Ceftin

PPhiladelphia Eye Associates

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteomyelitis1 trial

Chronic Non-bacterial Osteomyelitis Treated With Pamidronate

Unknown status·UUniversity of Aarhus·Phase 2·NCT02594878·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pamidronatdinatrium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pamidronatdinatrium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pamidronatdinatrium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Aarhus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Aarhus

Pamidronatdinatrium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteomyelitis1 trial

References

Drug Info

Quick Facts

Related News